Trial Now Recruiting: Observational Study of Responses to Treatments in Advanced Central Nervous System (CNS) Tumors (NCT07374692)
WHY IT MATTERS
This trial offers patients with recurrent or advanced brain tumors access to personalized drug testing that could identify the most effective treatment for their specific tumor type within weeks of surgery.
Researchers are testing a new technology called SmartMatch that helps doctors find the best cancer medicines for patients with rare brain and spinal cord tumors. The technology works by taking a small piece of tumor removed during surgery and testing it against different drugs to see which ones work best. The study wants to see if SmartMatch can complete this analysis and give doctors a report within 3 weeks of surgery. This trial is looking for 80 patients with various types of brain tumors.
NCT ID: NCT07374692 Status: RECRUITING Conditions: Recurrent CNS Tumors, Brain Cancer, Gliomas, IDH-wildtype Gliomas, IDH-mutant Gliomas, Rare CNS Tumor Phase: NA Enrollment: 80 Sponsor: National Cancer Institute (NCI) Summary: Background: Primary central nervous system (CNS) tumors grow in the brain and spinal cord. These tumors are rare, but they are difficult to treat and often fatal. SmartMatch is a new technology that tries to help find the best medicines for the particular tumor by testing how small pieces of surgically removed tumor tissue react to different drugs. The study team wants to see if SmartMatch can complete the analysis and generate a report within 21 days from the time of the surgery. Objective:
YOU CAN ACT ON THIS
If you have a recurrent or advanced CNS tumor and are considering surgery, ask your oncologist if you're eligible for this NCI-sponsored trial (NCT07374692) at your treatment center.